阿托伐他汀和瑞舒伐他汀对短暂性脑缺血发作患者治疗价值分析

Analysis on Therapeutic Value of Atorvastatin and Rosuvastatin in Patients with Transient Ischemic Attack

目的:观察阿托伐他汀和瑞舒伐他汀治疗短暂性脑缺血发作患者的疗效。方法:2020年1-12月收治短暂性脑缺血发作患者60例,随机分为两组,各30例。对照组采用阿托伐他汀治疗;研究组采用瑞舒伐他汀治疗。比较两组治疗效果。结果:研究组治疗总有效率及生活质量各项评分均高于对照组,不良反应发生率低于对照组,差异有统计学意义(P<0.05)。研究组治疗后焦虑(SAS)及抑郁(SDS)评分均低于对照组,颈动脉内膜中层厚度(IMT)和斑块面积均小于对照组,差异有统计学意义(P<0.05)。结论:阿托伐他汀和瑞舒伐他汀治疗短暂性脑缺血发作患者均可以有效改善IMT和斑块面积,甚至消除颈动脉斑块,但瑞舒伐他汀效果更加显著。

Objective: To observe the efficacy of atorvastatin and rosuvastatin in the treatment of patients with transient ischemic attack. Methods: From January to December in 2020, 60 patients with transient ischemic attack were selected, they were randomly divided into the two groups with 30 cases in each group. The control group was treated with atorvastatin. The study group was treated with rosuvastatin. The treatment effects of the two groups were compared. Results: The total effective rate and quality of life scores in the study group were higher than those in the control group, and the incidence of adverse reactions was lower than that in the control group, the differences were statistically significant(P<0.05). The scores of self-rating anxiety scale(SAS) and self-rating depression scale(SDS) after treatment in the study group were lower than those in the control group, and the carotid artery intima-media thickness(IMT) and plaque area were less than those in the control group, the differences were statistically significant(P<0.05). Conclusion: Both atorvastatin and rosuvastatin can effectively reduce IMT and plaque area in patients with transient ischemic attack, and can even eliminate carotid plaque, but the effect of rosuvastatin is more obvious.